While very low-depend MBL seldom progresses to CLL, substantial-rely MBL progresses to CLL demanding therapy in a price of 1% to 2% a year. Superior-count MBL is distinguished from Rai 0 CLL depending on if the B-mobile rely is higher than or below 5 × 109/L. Though men and women with both equally superior-depend MBL and CLL Rai phase 0 are at inc